LINC01711 promotes transforming growth factor-beta (TGF-β) induced invasion in glioblastoma multiforme (GBM) by acting as a competing endogenous RNA for miR-34a and promoting ZEB1 expression

Shree, Bakhya; Sengar, Suryansh; Tripathi, Shraddha; Sharma, Vivek

doi:10.1016/j.neulet.2022.136937

Cited by 14 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LINC01711 is markedly expressed in esophageal cancer and has been linked to substandard prognosis by promoting tumor cells proliferation, migration, and invasion properties through FSCN1 upregulation and miR-326 downregulation 39 . Bakhya Shree et al confirmed that LINC01711 also promotes glioblastoma multiforme cells' proliferating, migrating and invading properties and is associated with its substandard prognosis 40 . ARNILA has been reported to have poor PFS and stimulated EMT, invasion, and metastasis in triple-negative breast cancer patients in vitro and in vivo 41 .…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer

Chen,

Qin,

Zhu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Telomerase allows eukaryotic cells to proliferate indefinitely, an important characteristic of tumor cells. Telomerase-related long no coding RNAs (TERLs) are involved in prognosis and drug sensitivity prediction; however, their association with bladder cancer (BLCA) is still unreported. The objective of this research is to determine a predictive prognostic TERL signature for OS and to provide an efficient treatment option for BLCA. The RNA sequence, clinical information, and mutational data of BLCA patients were acquired from The Cancer Genome Atlas (TCGA) database. With the help of the data from least absolute shrinkage and selection operator (LASSO) regression and Cox regression, a prognostic signature was established including 14 TERLs, which could divide BLCA patients into low-risk (L-R) and high-risk (H-R) cohorts. The time-dependent receiver operating characteristic (ROC) curve demonstrated the greater predictive power of the model. By combing the TERLs-based signature and clinical risk factors (age, sex, grade, and stage), a prognostic nomogram was constructed to forecast the survival rates of patients with BLCA at 1-, 3-, and 5-years, which was well matched by calibration plots C-index and Decision curve analysis (DCA). Furthermore, the L-R cohort showed higher tumor mutation burden (TMB) and lower tumor immune dysfunction and exclusion (TIDE) than the H-R cohort, as well as substantial variability in immune cell infiltration and immune function between the two cohorts was elucidated. As for external validation, LINC01711 and RAP2C-AS1 were identified as poor prognostic factors by survival analysis from the Kaplan–Meier Plotter database, which were validated in BLCA cell lines (EJ, 253J, T24, and 5637) and SV-HUC-1 cells as the control group using qRT-PCR. In addition, interference with the expression of RAP2C-AS1 suppresses the proliferation and migration of BLCA cells, and RAP2C-AS1 could affect the expression of CD274 and CTLA4, which could serve as prognostic markers and characterize the tumor microenvironment in BLCA. Overall, the model based on the 14-TERLs signature can efficiently predict the prognosis and drug treatment response in individuals with bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer

Chen,

Qin,

Zhu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The Matrigel-Transwell invasion assay, colony formation investigations, and wound healing assays all demonstrated that the capacity of GBM cells to invade was greatly reduced when GRIK1 was inhibited. The molecular mechanisms of GBM growth and invasion are extremely complex and include many factors, such as lactate dehydrogenases [ 36 ], mitogen-activated protein kinase kinase kinase 1(MAP3K1)/c-JUN signaling-axis [ 37 ], Hsa_circ_0072309 [ 38 ], RNA-binding motif protein 8A (RBM8A) [ 9 ], LINC01711 [ 10 ],COL1A2 [ 11 ], adipocyte enhancer-binding protein 1 (AEBP1) [ 39 ], Nucleobindin-2 [ 40 ], the cross-talk between Notch1 signaling and CXCL12/CXCR4 system [ 41 ], PRL1/USP36/Snail2 axis [ 42 ], Zinc finger CCCH-type containing 15 (ZC3H15) [ 43 ], circ_0060055 [ 44 ], and Rhoj/Rac1/PAK signaling [ 45 ], etc.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, it is important to explore GBM biology and determine new molecular targets relevant to the therapeutic effect. According to recent studies, there are many factors associated with glioma cell growth and invasion, such as Vav guanine nucleotide exchange factor 3 (VAV3) [ 9 ], long noncoding RNA LINC01711 (lncRNA-LINC01711) [ 10 ], collagen alpha-2(I) chain (COL1A2) [ 11 ], NIMA-related kinase 2 (NEK2) [ 12 ], and RAN binding protein 10 (RANBP10) [ 13 ], etc.…”

Section: Introductionmentioning

confidence: 99%

GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

HOU,

XU,

2024

View full text Add to dashboard Cite

Primary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable disease, and the median survival time of patients with GBM is shorter than 15 months. Thus, molecular mechanisms of GBM characteristic invasive growth need to be clarified to improve the poor prognosis. Glutamate ionotropic receptor kainate type subunit 1 (GRIK1) is essential for brain function and is involved in many mental and neurological diseases. However, GRIK1’s pathogenic roles and mechanisms in GBM are still unknown. Single-nuclear RNA sequencing of primary and recurrent GBM samples revealed that GRIK1 expression was noticeably higher in the recurrent samples. Moreover, immunohistochemical staining of an array of GBM samples showed that high levels of GRIK1 correlated with poor prognosis of GBM, consistent with The Cancer Genome Atlas database. Knockdown of GRIK1 retarded GBM cells growth, migration, and invasion. Taken together, these findings show that GRIK1 is a unique and important component in the development of GBM and may be considered as a biomarker for the diagnosis and therapy in individuals with GBM.

show abstract

“…ZEB1-AS1 (zinc finger E-box-binding homeobox 1 antisense 1) is an oncogenic GBM lncRNA [79]. Protumour ZEB1-AS1 is associated with several other malignancies, including colorectal cancer, breast cancer, gastric cancer, prostate cancer, hepatocellular carcinoma, non-small cell lung cancer, osteosarcoma, and others [310].…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are RNA molecules of 200 nucleotides or more in length that are not translated into proteins. Their expression is tissue-specific, with the vast majority involved in the regulation of cellular processes and functions. Many human diseases, including cancer, have been shown to be associated with deregulated lncRNAs, rendering them potential therapeutic targets and biomarkers for differential diagnosis. The expression of lncRNAs in the nervous system varies in different cell types, implicated in mechanisms of neurons and glia, with effects on the development and functioning of the brain. Reports have also shown a link between changes in lncRNA molecules and the etiopathogenesis of brain neoplasia, including glioblastoma multiforme (GBM). GBM is an aggressive variant of brain cancer with an unfavourable prognosis and a median survival of 14–16 months. It is considered a brain-specific disease with the highly invasive malignant cells spreading throughout the neural tissue, impeding the complete resection, and leading to post-surgery recurrences, which are the prime cause of mortality. The early diagnosis of GBM could improve the treatment and extend survival, with the lncRNA profiling of biological fluids promising the detection of neoplastic changes at their initial stages and more effective therapeutic interventions. This review presents a systematic overview of GBM-associated deregulation of lncRNAs with a focus on lncRNA fingerprints in patients’ blood.

show abstract

LINC01711 promotes transforming growth factor-beta (TGF-β) induced invasion in glioblastoma multiforme (GBM) by acting as a competing endogenous RNA for miR-34a and promoting ZEB1 expression

Cited by 14 publications

References 49 publications

Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer

Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer

GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

lncRNA Biomarkers of Glioblastoma Multiforme

Contact Info

Product

Resources

About